Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice

Kayla A. Quirin, Jason J. Kwon, Arafat Alioufi, Tricia Factora, Constance J. Temm, Max Jacobsen, George Sandusky, Kim Shontz, Louis G. Chicoine, K. Reed Clark, Joshua T. Mendell, Murray Korc, Janaiah Kota

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recombinant adeno-associated virus (rAAV)-mediated gene delivery shows promise to transduce the pancreas, but safety/efficacy in a neoplastic context is not well established. To identify an ideal AAV serotype, route, and vector dose and assess safety, we have investigated the use of three AAV serotypes (6, 8, and 9) expressing GFP in a self-complementary (sc) AAV vector under an EF1α promoter (scAAV.GFP) following systemic or retrograde pancreatic intraductal delivery. Systemic delivery of scAAV9.GFP transduced the pancreas with high efficiency, but gene expression did not exceed >45% with the highest dose, 5 × 1012 viral genomes (vg). Intraductal delivery of 1 × 1011 vg scAAV6.GFP transduced acini, ductal cells, and islet cells with >50%, ∼48%, and >80% efficiency, respectively, and >80% pancreatic transduction was achieved with 5 × 1011 vg. In a KrasG12D-driven pancreatic cancer mouse model, intraductal delivery of scAAV6.GFP targeted acini, epithelial, and stromal cells and exhibited persistent gene expression 5 months post-delivery. In normal mice, intraductal delivery induced a transient increase in serum amylase/lipase that resolved within a day of infusion with no sustained pancreatic inflammation or fibrosis. Similarly, in PDAC mice, intraductal delivery did not increase pancreatic intraepithelial neoplasia progression/fibrosis. Our study demonstrates that scAAV6 targets the pancreas/neoplasm efficiently and safely via retrograde pancreatic intraductal delivery.

Original languageEnglish (US)
Pages (from-to)8-20
Number of pages13
JournalMolecular Therapy - Methods and Clinical Development
Volume8
DOIs
StatePublished - Mar 16 2018

Fingerprint

Viral Genome
Pancreatic Neoplasms
Acinar Cells
Safety
Pancreas
Fibrosis
Genes
Gene Expression
Dependovirus
Amylases
Stromal Cells
Lipase
Islets of Langerhans
Epithelial Cells
Inflammation
Serum
Neoplasms
Serogroup

Keywords

  • AAV
  • AAV6
  • ERCP
  • gene therapy
  • intraductal
  • pancreatic cancer and pancreatitis
  • PDAC
  • retrograde pancreatic gene delivery
  • targeted gene delivery

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice. / Quirin, Kayla A.; Kwon, Jason J.; Alioufi, Arafat; Factora, Tricia; Temm, Constance J.; Jacobsen, Max; Sandusky, George; Shontz, Kim; Chicoine, Louis G.; Clark, K. Reed; Mendell, Joshua T.; Korc, Murray; Kota, Janaiah.

In: Molecular Therapy - Methods and Clinical Development, Vol. 8, 16.03.2018, p. 8-20.

Research output: Contribution to journalArticle

Quirin, KA, Kwon, JJ, Alioufi, A, Factora, T, Temm, CJ, Jacobsen, M, Sandusky, G, Shontz, K, Chicoine, LG, Clark, KR, Mendell, JT, Korc, M & Kota, J 2018, 'Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice', Molecular Therapy - Methods and Clinical Development, vol. 8, pp. 8-20. https://doi.org/10.1016/j.omtm.2017.09.006
Quirin, Kayla A. ; Kwon, Jason J. ; Alioufi, Arafat ; Factora, Tricia ; Temm, Constance J. ; Jacobsen, Max ; Sandusky, George ; Shontz, Kim ; Chicoine, Louis G. ; Clark, K. Reed ; Mendell, Joshua T. ; Korc, Murray ; Kota, Janaiah. / Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice. In: Molecular Therapy - Methods and Clinical Development. 2018 ; Vol. 8. pp. 8-20.
@article{22ca108c2bda4271b653c0b91ea51359,
title = "Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice",
abstract = "Recombinant adeno-associated virus (rAAV)-mediated gene delivery shows promise to transduce the pancreas, but safety/efficacy in a neoplastic context is not well established. To identify an ideal AAV serotype, route, and vector dose and assess safety, we have investigated the use of three AAV serotypes (6, 8, and 9) expressing GFP in a self-complementary (sc) AAV vector under an EF1α promoter (scAAV.GFP) following systemic or retrograde pancreatic intraductal delivery. Systemic delivery of scAAV9.GFP transduced the pancreas with high efficiency, but gene expression did not exceed >45{\%} with the highest dose, 5 × 1012 viral genomes (vg). Intraductal delivery of 1 × 1011 vg scAAV6.GFP transduced acini, ductal cells, and islet cells with >50{\%}, ∼48{\%}, and >80{\%} efficiency, respectively, and >80{\%} pancreatic transduction was achieved with 5 × 1011 vg. In a KrasG12D-driven pancreatic cancer mouse model, intraductal delivery of scAAV6.GFP targeted acini, epithelial, and stromal cells and exhibited persistent gene expression 5 months post-delivery. In normal mice, intraductal delivery induced a transient increase in serum amylase/lipase that resolved within a day of infusion with no sustained pancreatic inflammation or fibrosis. Similarly, in PDAC mice, intraductal delivery did not increase pancreatic intraepithelial neoplasia progression/fibrosis. Our study demonstrates that scAAV6 targets the pancreas/neoplasm efficiently and safely via retrograde pancreatic intraductal delivery.",
keywords = "AAV, AAV6, ERCP, gene therapy, intraductal, pancreatic cancer and pancreatitis, PDAC, retrograde pancreatic gene delivery, targeted gene delivery",
author = "Quirin, {Kayla A.} and Kwon, {Jason J.} and Arafat Alioufi and Tricia Factora and Temm, {Constance J.} and Max Jacobsen and George Sandusky and Kim Shontz and Chicoine, {Louis G.} and Clark, {K. Reed} and Mendell, {Joshua T.} and Murray Korc and Janaiah Kota",
year = "2018",
month = "3",
day = "16",
doi = "10.1016/j.omtm.2017.09.006",
language = "English (US)",
volume = "8",
pages = "8--20",
journal = "Molecular Therapy - Methods and Clinical Development",
issn = "2329-0501",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice

AU - Quirin, Kayla A.

AU - Kwon, Jason J.

AU - Alioufi, Arafat

AU - Factora, Tricia

AU - Temm, Constance J.

AU - Jacobsen, Max

AU - Sandusky, George

AU - Shontz, Kim

AU - Chicoine, Louis G.

AU - Clark, K. Reed

AU - Mendell, Joshua T.

AU - Korc, Murray

AU - Kota, Janaiah

PY - 2018/3/16

Y1 - 2018/3/16

N2 - Recombinant adeno-associated virus (rAAV)-mediated gene delivery shows promise to transduce the pancreas, but safety/efficacy in a neoplastic context is not well established. To identify an ideal AAV serotype, route, and vector dose and assess safety, we have investigated the use of three AAV serotypes (6, 8, and 9) expressing GFP in a self-complementary (sc) AAV vector under an EF1α promoter (scAAV.GFP) following systemic or retrograde pancreatic intraductal delivery. Systemic delivery of scAAV9.GFP transduced the pancreas with high efficiency, but gene expression did not exceed >45% with the highest dose, 5 × 1012 viral genomes (vg). Intraductal delivery of 1 × 1011 vg scAAV6.GFP transduced acini, ductal cells, and islet cells with >50%, ∼48%, and >80% efficiency, respectively, and >80% pancreatic transduction was achieved with 5 × 1011 vg. In a KrasG12D-driven pancreatic cancer mouse model, intraductal delivery of scAAV6.GFP targeted acini, epithelial, and stromal cells and exhibited persistent gene expression 5 months post-delivery. In normal mice, intraductal delivery induced a transient increase in serum amylase/lipase that resolved within a day of infusion with no sustained pancreatic inflammation or fibrosis. Similarly, in PDAC mice, intraductal delivery did not increase pancreatic intraepithelial neoplasia progression/fibrosis. Our study demonstrates that scAAV6 targets the pancreas/neoplasm efficiently and safely via retrograde pancreatic intraductal delivery.

AB - Recombinant adeno-associated virus (rAAV)-mediated gene delivery shows promise to transduce the pancreas, but safety/efficacy in a neoplastic context is not well established. To identify an ideal AAV serotype, route, and vector dose and assess safety, we have investigated the use of three AAV serotypes (6, 8, and 9) expressing GFP in a self-complementary (sc) AAV vector under an EF1α promoter (scAAV.GFP) following systemic or retrograde pancreatic intraductal delivery. Systemic delivery of scAAV9.GFP transduced the pancreas with high efficiency, but gene expression did not exceed >45% with the highest dose, 5 × 1012 viral genomes (vg). Intraductal delivery of 1 × 1011 vg scAAV6.GFP transduced acini, ductal cells, and islet cells with >50%, ∼48%, and >80% efficiency, respectively, and >80% pancreatic transduction was achieved with 5 × 1011 vg. In a KrasG12D-driven pancreatic cancer mouse model, intraductal delivery of scAAV6.GFP targeted acini, epithelial, and stromal cells and exhibited persistent gene expression 5 months post-delivery. In normal mice, intraductal delivery induced a transient increase in serum amylase/lipase that resolved within a day of infusion with no sustained pancreatic inflammation or fibrosis. Similarly, in PDAC mice, intraductal delivery did not increase pancreatic intraepithelial neoplasia progression/fibrosis. Our study demonstrates that scAAV6 targets the pancreas/neoplasm efficiently and safely via retrograde pancreatic intraductal delivery.

KW - AAV

KW - AAV6

KW - ERCP

KW - gene therapy

KW - intraductal

KW - pancreatic cancer and pancreatitis

KW - PDAC

KW - retrograde pancreatic gene delivery

KW - targeted gene delivery

UR - http://www.scopus.com/inward/record.url?scp=85043599659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043599659&partnerID=8YFLogxK

U2 - 10.1016/j.omtm.2017.09.006

DO - 10.1016/j.omtm.2017.09.006

M3 - Article

VL - 8

SP - 8

EP - 20

JO - Molecular Therapy - Methods and Clinical Development

JF - Molecular Therapy - Methods and Clinical Development

SN - 2329-0501

ER -